Clinical Trial Update: An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease [Phase 3]

View source ↗

Summary

Open-label Phase 3 trial update of vedolizumab in ulcerative colitis and Crohn's disease; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Ulcerative Colitis

Drugs mentioned

• Vedolizumab (vedolizumab)

Snippet

Sponsor: Takeda | Conditions: Ulcerative Colitis, Crohn's Disease | Phase 3 | Status: COMPLETED | Results posted: 2019-03-12